Related Experiment Video
Updated: Jun 24, 2025
Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease
Published on: February 3, 2012
Genetic study of the CDKN2A and CDKN2B genes in renal cell carcinoma patients
Nattaradee Kiatprungvech1, Premsant Sangkum1, Rozita Malinee2
1Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Objectives:
While recent studies have demonstrated several genetic alterations are associated with pathogenesis of RCC, the significance of cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase inhibitor 2B (CDKN2B) in tumorigenesis of RCC is less clear. We investigate the distribution of CDKN2A and CDKN2B mutations in patients with RCC and analyze the impact of CDKN2A and CDKN2B mutations on RCC.
Methods:
A pathological examination was conducted using thirty fresh renal tissue samples with renal masses that had undergone partial or radical nephrectomy. Multiplex ligation-dependent probe amplification (MLPA) was used to detect genetic aberrations of CDKN2A and CDKN2B in genomic DNA isolated from samples. Subsequently, CDKN2A and CDKN2B mutations were confirmed using chromosomal microarray technique.
Results:
Twenty-one patients were diagnosed with RCC, eight with benign diseases, including angiomyolipoma (AML) and oncocytoma, and one with mucinous adenocarcinoma of renal pelvis. Two of twenty-one patients (9.5 %) with clear-cell RCC were positive for CDKN2A and CDKN2B gene deletions. Interestingly, patients with CDKN2A and CDKN2B mutations were associated with sarcomatoid patterns of RCC (2 out of 4, 50 %). In contrast, no CDKN2A or CDKN2B deletions were detected in samples from benign renal tumors, papillary RCC, or other kidney cancers.
Conclusions:
This study demonstrated the potential use of CDKN2A and CDKN2B as biomarkers for the prognostic and molecular classification of renal cancer. CDKN2A and CDKN2B mutations may be associated with RCC development and sarcomatoid changes. Further research is needed to understand the underlying molecular mechanisms of CDKN2A and CDKN2B in the pathogenesis of RCC.
Insights
Mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A) and 2B (CDKN2B) genes were investigated in renal cell carcinoma (RCC). These gene mutations were found in clear-cell RCC and associated with sarcomatoid changes, suggesting their role in RCC progression.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Genetic alterations are implicated in renal cell carcinoma (RCC) pathogenesis.
- The specific roles of cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase inhibitor 2B (CDKN2B) in RCC tumorigenesis require further elucidation.
Purpose of the Study:
- To investigate the prevalence of CDKN2A and CDKN2B mutations in RCC patients.
- To analyze the impact of CDKN2A and CDKN2B mutations on RCC development and characteristics.
Main Methods:
- Pathological examination of 30 renal tissue samples.
- Multiplex ligation-dependent probe amplification (MLPA) to detect genetic aberrations in CDKN2A and CDKN2B.
- Chromosomal microarray technique for mutation confirmation.
Main Results:
- CDKN2A and CDKN2B gene deletions were identified in 9.5% of clear-cell RCC patients.
- Mutations in CDKN2A and CDKN2B were associated with sarcomatoid patterns in 50% of affected RCC cases.
- No CDKN2A or CDKN2B deletions were found in benign renal tumors or other kidney cancer subtypes.
Conclusions:
- CDKN2A and CDKN2B may serve as biomarkers for prognostic and molecular classification of renal cancer.
- CDKN2A and CDKN2B mutations are potentially linked to RCC development and sarcomatoid differentiation.
- Further research is warranted to understand the molecular mechanisms of CDKN2A and CDKN2B in RCC pathogenesis.
More Related Videos
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
13:15Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1
Published on: February 25, 2016
Related Concept Videos
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:34Inhibition of Cdk Activity
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...